Eli Lilly and Company arrives at Wednesday's Q2 release with the stock having retreated from its all-time high, options hedging re-intensifying to the highest level of the past year, and short sellers holding their rebuilt positions — a setup that has grown more cautious, not less, since the prior notes flagged the initial surge.
The options signal has sharpened further since last Tuesday's trader note. The put/call ratio has climbed to 1.3758, now matching the 52-week high — and running nearly 1.5 standard deviations above its 20-day average of 1.21. The direction of travel over the past two weeks is hard to ignore: the PCR rose from 1.01 in early July to 1.14 by mid-month, then accelerated sharply through the final week of July. That trajectory reflects mounting demand for downside protection, not a one-day spike. Meanwhile the stock has pulled back to $1,148.84, down 4.2% on the month and 3.9% on the week — giving back the all-time-high territory that briefly appeared in late July and noted in prior coverage. The combination of falling price and rising put demand marks a meaningful shift from the setup two weeks ago.
Short interest remains elevated but has eased fractionally from its July 24 peak. SI % of free float is 1.14%, down slightly from the 1.17% spike recorded when the previous reports were filed — but the weekly change is still up nearly 17%, confirming shorts maintained the bulk of positions built over the past fortnight. The lending market offers no constraint whatsoever. Availability is effectively unlimited, with over 640 million shares available to borrow, and the cost to borrow has fallen 35% over the past week to just 0.35%. Shorts are staying by choice, not inertia.
The analyst community remains broadly constructive, though the debate has sharpened. The bull case rests on tirzepatide's durability, Forglipron's launch potential, and a pipeline that spans oncology, neuroscience, and immunology — areas where Lilly's Growth and Quality scores both rank highly at the stock level. Multiple firms raised targets through mid-July, with Citigroup taking their target to $1,600 and JPMorgan moving to $1,400. The mean consensus target is $1,277 — around 11% above the current price. Bears focus on the risk of a slower tirzepatide Rx trajectory, Forglipron launch disappointment, and pricing pressure — and point to a P/E near 28x alongside EPS forward growth ranked in just the 24th percentile, a valuation profile that demands execution rather than optionality. Lilly's most recent print, in late April, produced a one-day gain of 13% and a five-day move of nearly 15% — a reminder that the stock's historical reaction range in either direction is wide.
Wednesday's print is therefore less about Lilly's long-term competitive position in GLP-1 — which the Street broadly accepts — and more about whether tirzepatide volume data and Forglipron guidance can justify a multiple that has already retreated from its highs with the PCR at its most defensive of the year.
See the live data behind this article on ORTEX.
Open LLY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
